Nonclinical studies play a critical role in new drug development. These studies are conducted to assess a drug’s efficacy, safety, and behavior in the body, and to evaluate its potential before advancing to clinical trials. Below are typical types of nonclinical studies.
Pharmacology (efficacy) studies evaluate how a drug acts against a specific disease. In particular, they examine the extent to which the intended therapeutic effect is achieved and, where applicable, the mechanism of action. Animal and cell-based models are used to determine whether the expected effect is observed. The results provide essential evidence of efficacy and form the foundational data to proceed to clinical studies.
Safety (toxicology) studies evaluate the degree to which a drug is safe for human use. These studies identify potential adverse effects and toxicities and generate data to inform appropriate dosing. Using animal studies and other models, both short-term and long-term effects are examined. This work helps minimize risk in humans and helps ensure that clinical trials can proceed on a sound safety basis.
Pharmacokinetic studies assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) in the body. The objective is to clarify how the drug moves through the body and what changes occur along the way. PK results are important for dose selection and dosing regimen decisions and provide core data that can help predict a drug’s safety and efficacy.
Toxicity studies evaluate the degree of toxicity a drug may exert. They determine whether the drug has harmful effects on specific organs or tissues. Typical designs include acute, subacute, and chronic toxicity studies, which assess effects after single or repeated/long-term dosing. Results establish the drug’s safety profile and support clinical trial design.
Carcinogenicity studies evaluate whether long-term use of a drug could increase the risk of cancer. These studies are typically conducted in animal models to determine whether prolonged exposure promotes tumor development in specific organs or tissues. The results provide important data for risk assessment and risk management in defined patient populations.
Nonclinical studies are an essential stage in new drug development, used to evaluate efficacy, safety, pharmacokinetics, toxicity, and carcinogenicity. Their results support benefit–risk assessment before clinical entry and provide foundational data to establish appropriate dosing and therapeutic approaches. Accurate and rigorous execution of these studies is critical to development success.
In drug discovery, the quality and efficiency of non-clinical studies have a direct impact on clinical success rates, development costs, and overall length of time required in R&D.
In recent years, there has been more demand for clinically relevant data, globally accepted reliability, and accurate early-stage screening.
Thus, it is more important than ever to select the right CRO (Contract Research Organization) for strategic approach.
In this article, we highlight three CROs with proven technical capabilities, expertise, and long standing track records. These are our TOP 3 choices based on their capabilities and the specific target goals of the researchers for their non-clinical studies.